If you have been reading about CJC-1295 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-09-19. Numbers and descriptions here follow the published literature rather than marketing material.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
Laboratory handling centers on minimizing exposure to water, heat and oxygen before use. Working solutions are typically prepared in sterile water or a mild buffer, and any residual particulate matter is removed by filtration. When the powder dissolves slowly, a small proportion of acetonitrile or dilute acetic acid is sometimes added as a co-solvent. Containers are kept sealed and desiccated between uses. Records of lot number, reconstitution date and storage conditions support later comparison of results across experiments.
Identity and purity are established with reversed phase high performance liquid chromatography coupled to mass spectrometry. The chromatographic step separates the target peptide from truncated sequences and deletion products, while the mass measurement confirms the expected molecular weight to within a fraction of a dalton. Because the two common variants differ by the presence of the linker, mass alone can distinguish them in the unconjugated state. Amino acid analysis and peptide mapping are used when sequence level confirmation is required.
Lyophilized material is generally stable for extended periods when held at minus twenty degrees Celsius or below and protected from moisture and light. In solution the peptide is more labile; bond hydrolysis, aggregation and oxidation of susceptible residues all proceed faster at ambient temperature. Repeated freeze and thaw cycles should be avoided because they promote clumping and loss of soluble material. The conjugated variant adds a further consideration, since the maleimide group can hydrolyze in aqueous buffer and lose its ability to react with albumin.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (no linker) | ~3.37 kDa | Calculated from peptide sequence |
| Molecular weight (with linker) | ~3.65 kDa | Includes albumin-binding moiety |
| Appearance | White to off-white powder | Typically lyophilized |
| Solubility | Soluble in water | Also dissolves in aqueous buffers |
| Common synonyms | Modified GRF(1-29), DAC:GRF | Usage varies by source |
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
==== MeSH D12.776.964.700.750 – retroviridae proteins, oncogenic ==== MeSH D12.776.964.700.750.320 – fusion proteins, gag-onc MeSH D12.776.964.700.750.320.700 – oncogene protein p65(gag-jun) MeSH D12.776.964.700.750.470 – gene products, rex MeSH D12.776.964.700.750.480 – gene products, tax (gene) MeSH D12.776.964.700.750.650 – oncogene protein gp140(v-fms) MeSH D12.776.964.700.750.710 – oncogene protein p21(ras) MeSH D12.776.964.700.750.750 – oncogene protein p55(v-myc) MeSH D12.776.964.700.750.760 – oncogene protein pp60(v-src) MeSH D12.776.964.700.750.817 – oncogene protein v-maf MeSH D12.776.964.700.750.875 – oncogene proteins v-abl MeSH D12.776.964.700.750.882 – oncogene proteins v-erba MeSH D12.776.964.700.750.883 – oncogene proteins v-erbb MeSH D12.776.964.700.750.887 – oncogene proteins v-fos MeSH D12.776.964.700.750.900 – oncogene proteins v-mos MeSH D12.776.964.700.750.903 – oncogene proteins v-myb MeSH D12.776.964.700.750.920 – oncogene proteins v-raf MeSH D12.776.964.700.750.925 – oncogene proteins v-rel MeSH D12.776.964.700.750.935 – oncogene proteins v-sis
== Pharmacology == The pharmacology of 5α-reductase inhibition is complex, but involves the binding of NADPH to the enzyme followed by the substrate. Specific substrates include testosterone, progesterone, androstenedione, epitestosterone, cortisol, aldosterone, and deoxycorticosterone. The entire physiologic effect of their reduction is unknown, but likely related to their excretion or is itself physiologic. 5α-Reductase reduces the steroid Δ4,5 double bond in testosterone to its more active form DHT. Thus, inhibition results in decreased amounts of DHT. Because of this, slight elevations in testosterone and estradiol levels occur. The 5α-reductase reaction is a rate-limiting step in the testosterone reduction and involves the binding of NADPH to the enzyme followed by the substrate.
=== Food safety === In 2003, the Codex Alimentarius removed any upper dose limit for food irradiation as well as clearances for specific foods, declaring that all are safe to irradiate. Countries such as Pakistan and Brazil have adopted the Codex without any reservation or restriction. Standards that describe calibration and operation for radiation dosimetry, as well as procedures to relate the measured dose to the effects achieved and to report and document such results, are maintained by the American Society for Testing and Materials (ASTM international) and are also available as ISO/ASTM standards. All of the rules involved in processing food are applied to all foods before they are irradiated.
One should expect that, within a few thousand years of its entering the stage of industrial development, any intelligent species should be found occupying an artificial biosphere which surrounds its parent star. Dyson conceived that such structures would be clouds of asteroid-sized space habitats, though science fiction writers have preferred a solid structure: either way, such an artifact is often called a Dyson sphere, although Dyson used the term "shell". Dyson said that he used the term "artificial biosphere" in the article to mean a habitat, not a shape. The general concept of such an energy-transferring shell had been created decades earlier by science fiction writer Olaf Stapledon in his 1937 novel Star Maker, a source which Dyson credited publicly. Freeman Dyson was interviewed by Robert Wright in 2003 and the Dyson Sphere topic was broached. In response he stated that the paper he wrote on this concept was intended to be a joke and had nothing to do with work. He added that it amused him that he had become famous only for the things he didn't think were serious.
Oxa-noribogaine is an atypical κ-opioid receptor agonist of the "oxa-iboga" family and a synthetic benzofuran analogue of noribogaine. Although it still binds to hERG with similar avidity as noribogaine, it appears to be devoid of the proarrhythmic side effects of noribogaine.
Sources: en.wikipedia.org
== Motivation == The dramatic increase in genome sequencing technology has caused the number of protein sequences deposited into public databases to grow apparently exponentially. To cope with the influx of sequences, databases use computational predictions to auto-annotate individual protein's functions. While these computational methods offer the advantages of being extremely high-throughput and generally provide accurate broad classifications, exclusive use has led to a significant level of misannotation of enzyme function in protein sequence databases. Thus although the information now available represents an unprecedented opportunity to understand cellular metabolism across a wide variety of organisms, which includes the ability to identify molecules and/or reactions that may benefit human quality of life, the potential has not been fully actualized. The biological community's ability to characterize newly discovered proteins has been outstripped by the rate of genome sequencing, and the task of assigning function is now considered the rate-limiting step in understanding biological systems in detail.
doi:10.1016/S0733-8627(05)70156-5. PMID 11130936. Chantelau E., Schiffers T., Schutze J., Hansen B. (1997). "Effect of patient-selected intensive insulin therapy on quality of life". Patient Education and Counseling. 38 (2): 167–713. doi:10.1016/S0738-3991(96)00964-0. PMID 9128618.{{cite journal}}: CS1 maint: multiple names: authors list (link) Crawford L.M., Sinha R.N., Odell R.M., Comi R.J. (2000). "Efficacy of insulin pump therapy: mealtime delivery is the key factor". Endocrine Practice. 6 (3): 239–43. doi:10.4158/EP.6.3.239. PMID 11421538.{{cite journal}}: CS1 maint: multiple names: authors list (link) The DCCT Research Group. JAMA. 1997;227(5):374-4 Skyler J.S. Diabtes Technol Ther. 2000. The DCCT Research Group. Progression of retinopathy with intensive versus conventional treatment in the diabetes control and complications trial. 1994. The DCCT/EDIC Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. NEJM 2005; 353(25): 2643–2653. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus Diabetes Care 2001; 24: 1. Kaufman FR (2001). "A Pilot Study of the Continuous Glucose Monitoring System: Clinical decisions and glycemic control after its use in pediatric type 1 diabetic subjects". Diabetes Care. 24 (12): 2030–4. doi:10.2337/diacare.24.12.2030. PMID 11723078. Floyd J.C., Cornell R.G.; et al. (1993). "A prospective study identifying risk factors for discontinuance of insulin pump therapy".
=== Intermittent === Contrary to classic and intermediate MSUD, intermittent MSUD individuals will have normal growth and intellectual development. This type of MSUD is typically presented around 1 to 2 years of life. Other symptoms may include ataxia and semicoma. These symptoms may accelerate and worsen rapidly. Symptoms of lethargy and characterized odor of maple syrup will occur when the individual experiences stress, does not eat or develops an infection. The metabolic crisis leading to seizures, coma, and brain damage is still a possibility.
Reismanis was an information technology consultant at Accenture and intended to keep ModDB his hobby, but he left the firm to found DesuraNET as the website's hosting company, citing the expense of running the website and his recollection of IGN's 2006 attempt to acquire it. ModDB was integrated into DesuraNET's Desura, which was a digital distribution service that focused on indie games. The service opened in April 2010 as a competitor to Valve's Steam.
Sources: en.wikipedia.org
== Incident and aftermath == RaDonda Vaught began work as a nurse at Vanderbilt University Medical Center in December 2015. On December 24, 2017, 75-year-old Charlene Murphey was admitted to the hospital for a subdural hematoma. Two days later, Vaught, a registered nurse, was instructed to administer Versed (midazolam, a sedating drug) to Murphey, but instead administered vecuronium (a paralyzing drug). Murphey was to be given Versed prior to an MRI scan. Vaught initially tried to withdraw Versed from an automated dispensing cabinet which was designed to communicate with the hospital's Medication Administration Record (MAR). Though an order for the intended medication (Versed) was present in Murphey's MAR, Vaught "couldn't find [it] in Murphey's profile" in the dispensing cabinet after typing "VE" into its search function without realizing she should have been looking for its generic name, midazolam. Vaught then triggered an override that unlocked a much larger swath of medications and then searched for "VE" again, and selected the first medication in the list (vecuronium). Vaught claimed that using overrides was a common and daily occurrence; other witnesses similarly testified that technical issues and delays at medication cabinets were common, and that "nurses could use overrides to overcome those delays." Vaught looked at the back of the vial and saw that it needed to be reconstituted, but did not look at the front of the vial to verify that it was, indeed, Versed. Vaught proceeded to reconstitute the vial, went to the imaging unit, and administered a dose to Murphey.
February 2: Decree establishing an agricultural action committee in every rural municipality and cantonal agricultural organization committees; women managing such farms have the right to vote in these committees. December 27: Law increasing penalties for specific forms of vagrancy; this notably concerns procuring. 1917
In August, the Federal Police (PF) launched Operations Carbono Oculto, Quasar and Tank against a multibillion-real scheme of fraud in the fuel sector and money laundering, revealing that the First Capital Command (PCC) and companies in the financial market used fintechs and transactions via PIX to move and conceal large sums. According to the investigation, the absence of oversight, intensified by the disinformation that circulated on social media about the new Federal Revenue Service oversight rule that would be implemented at the beginning of the year but was revoked due to fake news, facilitated the criminal group's activity. Later, deputies requested the investigation of Nikolas over the video in which he criticized the new oversight of financial movements via Pix."These fake news were so strong that, despite all the effort of the Federal Revenue Service, we could not overcome these lies, because of the strength of those who boosted them. [...] And today's operations show who gained from these lies, from these fake news". — Robinson Barreirinhas, special secretary of the Federal Revenue Service.
== Structural classes == Enzyme inhibitors are a chemically diverse set of substances that range in size from organic small molecules to macromolecular proteins. Small molecule inhibitors include essential primary metabolites that inhibit upstream enzymes that produce those metabolites. This provides a negative feedback loop that prevents over production of metabolites and thus maintains cellular homeostasis (steady internal conditions). Small molecule enzyme inhibitors also include secondary metabolites, which are not essential to the organism that produces them, but provide the organism with an evolutionary advantage, in that they can be used to repel predators or competing organisms or immobilize prey. In addition, many drugs are small molecule enzyme inhibitors that target either disease-modifying enzymes in the patient or enzymes in pathogens which are required for the growth and reproduction of the pathogen. In addition to small molecules, some proteins act as enzyme inhibitors. The most prominent example are serpins (serine protease inhibitors) which are produced by animals to protect against inappropriate enzyme activation and by plants to prevent predation. Another class of inhibitor proteins is the ribonuclease inhibitors, which bind to ribonucleases in one of the tightest known protein–protein interactions. A special case of protein enzyme inhibitors are zymogens that contain an autoinhibitory N-terminal peptide that binds to the active site of enzyme that intramolecularly blocks its activity as a protective mechanism against uncontrolled catalysis.
== Drug interactions == Smoking is known to increase levels of liver enzymes that break down drugs and toxins. That means that drugs cleared by these enzymes are cleared more quickly in smokers, which may result in the drugs not working. Specifically, levels of CYP1A2 and CYP2A6 are induced: substrates for 1A2 include caffeine and tricyclic antidepressants such as amitriptyline; substrates for 2A6 include the anticonvulsant valproic acid.
Sources: en.wikipedia.org
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.
Early development used the albumin-binding form, and a shorter variant was later discussed under the same label. Because the two differ in half-life and handling, ambiguity arises whenever a source omits the variant designation.
The compound derives from that fragment but is not identical to it. The parent fragment lacks the stabilizing substitutions, so its degradation rate and duration of action differ noticeably.
The mass difference from the linker is large enough for routine detection by mass spectrometry. The unconjugated form gives a single sharp signal at its expected weight. Material that has already reacted with albumin shows a much higher mass and a broadened chromatographic peak.